N-Cadherin has an important role during dendrite arborization, axon guidance, and synaptogenesis. In particular, at synaptic sites, N-cadherin is involved in the regulation of cell-cell adhesion and in morphology and plasticity control. Recent studies have shown that N-cadherin can be cleaved by the metalloproteinase ADAM10. Here we demonstrate that impairing ADAM10 localization and activity at synaptic sites decreases its processing of N-cadherin. This leads to an accumulation of the full-length form of N-cadherin, to an increase in spine head width, and to modifications of the number and function of glutamate receptors of AMPA type, both in vitro and in vivo. Our results indicate a key role for ADAM10 in the complex sequence of events through which N-cadherin affects spine maturation and controls structure and function of glutamatergic synapses.
Introduction
Glutamate released at excitatory synapses acts toward different types of ionotropic glutamate receptors (iGluRs): kainate, AMPA, and NMDA type (Dingledine et al., 1999; Nusser, 2000; Pinheiro and Mulle, 2006; Newpher and Ehlers, 2008) . Clustering of iGluRs at synaptic sites and their subunit composition influence the synaptic response evoked by given stimuli (Greger et al., 2007; Lau and Zukin, 2007) . Identification of the mechanisms governing composition and the number of active iGluRs at synapses is necessary to understand their role in synaptic activity and plasticity.
Different classes of cell adhesion molecules, such as cadherins (Boggon et al., 2002; Bamji, 2005) , are involved in the regulation of synaptic trafficking and stabilization of iGluRs. N-Cadherin has a key role during dendrite arborization, axon guidance, and synaptogenesis (Benson and Tanaka, 1998; Yu and Malenka, 2003) . Moreover, at synapses, N-cadherin regulates synaptic adhesion, spine morphology, and activity-dependent plasticity (Togashi et al., 2002; Okamura et al., 2004; Xie et al., 2008; Mendez et al., 2010) . Recent studies also showed that N-cadherin is mandatory for an increase in AMPA receptor content and function at synaptic sites (Liao et al., 1999; Okuda et al., 2007; Saglietti et al., 2007; Tai et al., 2008; Xie et al., 2008) , which is associated with spine enlargement (Kasai et al., 2003; Abe et al., 2004; Mendez et al., 2010) . Thus, a temporal and functional relationship between N-cadherin, synaptic accumulation of AMPA receptors, and spine growth has been put forward (Zito et al., 2009) .
Recent data showed that N-cadherin can be cleaved by ADAM10 (a disintegrin and metalloproteinase 10). Via its metalloproteinase domain, the enzyme is responsible for the initial step of N-cadherin processing (Reiss et al., 2005; Uemura et al., 2006) , which, extracellularly, releases soluble active fragments and, intracellularly, generates a C-terminal fragment (CTF). CTF initiates signaling pathways through the cytoplasmic ␤-catenin pool (Fahrenholz and Postina, 2006; Reiss et al., 2006) . Therefore, ADAM10-dependent cleavage of N-cadherin modulates cell-cell adhesion as well as signal transduction. ADAM10 shows postsynaptic localization (Janes et al., 2005; Marcello et al., 2007) permitted by association with synapse-associated protein-97 (SAP97), a member of the postsynaptic density (PSD)-membrane-associated guanylate kinase (MAGUK) protein family. Perturbing ADAM10/SAP97 association impairs ADAM10 localization in the postsynaptic membrane and decreases ADAM10 activity toward synaptic substrates (Marcello et al., 2007) .
What are the consequences of ADAM10 activity on N-cadherin at synaptic sites? And how may this processing contribute to spine remodeling and availability/stabilization of active iGluRs, which have been described as linked to N-cadherin? To tackle this issue, we used the tissue inhibitor of metalloproteinase-1 (TIMP-1), an ADAM10 inhibitor, as well as a cell-permeable peptide (TATPro) able to interfere in vitro and in vivo with ADAM10 synaptic localization and activity. Inhibition of ADAM10 activity on N-cadherin induced a significant increase in size of dendritic spines and a modification of the number and the currents of synaptic AMPA receptors.
3 D 715 as described previously (Uemura et al., 2006) . Immunoprecipitation. Fifty micrograms of homogenate from cultured hippocampal neurons, acute hippocampal slices, or mouse brain treated with both TAT-Pro and TAT-Ala peptides were incubated in RIA buffer (200 mM NaCl, 10 mM EDTA, 10 mM Na 2 HPO 4 , 0.5% NP-40, and 0.03% SDS) in a final volume of 200 l with antibody against ADAM10 N-terminal domain overnight at 4°C. Protein A-Sepharose beads (SigmaAldrich) were added, and incubation was continued for 2 h, at room temperature, with shaking. Beads were collected by centrifugation at 1000 ϫ g for 5 min and washed three times with RIA buffer before adding sample buffer for SDS-PAGE and boiling for 5 min. Beads were collected by centrifugation, and all supernatants were applied onto 6% SDS-PAGE.
Animal treatment. Two-week-old mice (Charles River) received a single intraperitoneal injection of either TAT-Pro (3 nmol/g) or TAT-Ala peptide (3 nmol/g) diluted in sterile saline solution (Marcello et al., 2007) . Animals were killed after 24 h, and the brains were rapidly removed. All experimental procedures were performed with care to minimize discomfort and pain to treated animals, in accordance with the guidelines of the European Communities Council (Directive 86/609/ EEC of November 24, 1986). One hemisphere of each animal was homogenized in 0.32 M ice-cold sucrose containing 1 mM HEPES, 1 mM MgCl 2 , 1 mM EDTA, 1 mM NaHCO 3 , and 0.1 mM PMSF, pH 7.4, in the presence of a complete set of proteases inhibitors (Complete; GE Healthcare) and phosphatase inhibitors (Sigma-Aldrich). The homogenized tissue was centrifuged at 1000 ϫ g for 10 min. The resulting supernatant (S1) was centrifuged at 13,000 ϫ g for 15 min to obtain a crude membrane fraction (P2 fraction). The pellet was resuspended in 1 mM HEPES plus Complete in a glass-glass homogenizer and centrifuged at 100,000 ϫ g for 1 h. The pellet (P3) was resuspended in buffer containing 75 mM KCl and 1% Triton X-100 and centrifuged at 100,000 ϫ g for 1 h. The final pellet [P4, Triton-insoluble postsynaptic fraction (TIF)] was homogenized in 20 mM HEPES plus Complete in a glass-glass homogenizer.
Acute hippocampal slices, neuronal culture preparation, and transfection. Acute hippocampal slices were prepared as described previously (Gardoni et al., 2001 (Gardoni et al., , 2003 . Slices were quickly frozen at Ϫ80°C after pharmacological treatments. Hippocampal neuronal primary cultures were prepared from embryonic day 18 -19 rat hippocampi as described Figure 1 . ADAM10/SAP97 interaction is required for ADAM10-mediated cleavage of synaptic N-cadherin. A, DIV10 primary hippocampal neurons were treated with TAT-Ala and TAT-Pro ADAM10 peptides (10 M, 30 min) and lysed. ADAM10 was immunoprecipitated (IP) from total homogenate with an antibody raised against its N-terminal domain, and Western blot (WB) analysis was performed with an antibody against SAP97. Treatment with TAT-Pro was able to reduce coimmunoprecipitation of SAP97 with ADAM10 ( p Ͻ 0.005; n ϭ 3) compared with TAT-Ala. B, Western blot analysis performed in total homogenate with antibodies against ADAM10 and SAP97: no change in ADAM10 ( p ϭ 0.4423; n ϭ 7) and SAP97 ( p ϭ 0.7692; n ϭ 7) levels was observed. C, Western blot analysis performed in TIF with antibodies against ADAM10 and SAP97. TAT-Pro decreased ADAM10 ( p Ͻ 0.0005; n ϭ 7) but not of SAP97 ( p ϭ 0.8488; n ϭ 7) localization in the TIF. D, DIV10 primary hippocampal neurons were immunolabeled for ADAM10 (green) and Shank (red) as the postsynaptic marker. TAT-Pro ADAM10 peptide decreased ADAM10/Shank colocalization ( p Ͻ 0.05; n ϭ 10). E, Western blot analysis performed in TIF with an antibody against the C-terminal domain of N-cadherin. Treatment with TAT-Pro induced a statistically significant increase, when compared with TAT-Ala, in N-cadherin FL in the TIF ( p Ͻ 0.05; n ϭ 7), a concomitant decrease in CTF ( p Ͻ 0.05; n ϭ 7), and a consequent increase in the FL/CTF ratio ( p Ͻ 0.005; n ϭ 6).
previously (Piccoli et al., 2007) . Neurons were transfected at 7 d in vitro (DIV7) with GFP, DS-RED, GFP-N-cadherin wild type (Wt), and GFP-N-cadherin GD constructs using the calcium-phosphate method.
Subcellular fractionation and surface expression assay. TIFs were isolated from neurons as described previously (Gardoni et al., 2009) . Crosslinking experiments by means of bis(sulfosuccinimidyl) suberate (Bs 3 ) (Pierce) were performed as described previously (Hall and Soderling, 1997; Mauceri et al., 2004) .
Immunocytochemistry. Transfected neurons treated with both TATPro and TAT-Ala peptide (10 M, 30 min) were fixed for 30 min in 4% paraformaldehyde at room temperature and immunostained for GFP; primary and secondary antibodies were applied in GDB buffer (30 mM phosphate buffer, pH 7.4, containing 0.2% gelatin, 0.5% Triton X-100, and 0.8 M NaCl) (Sala et al., 2001 ). Cells were chosen randomly for quantification from four different coverslips (two independent experiments), and 14 neurons for each treatment were analyzed. Fluorescence images were acquired by using the confocal LSM510 Meta system (Zeiss) with a 63ϫ objective and a sequential acquisition setting at 1024 ϫ 1024 pixel resolution; for each image, three to four 1 m sections were acquired, and z-projection was obtained.
For colocalization studies, hippocampal neurons treated with TATPro and TAT-Ala peptide (10 M, 30 min), or with TIMP-1 (15 nM, 30 min), were fixed for 30 min in 4% paraformaldehyde at room temperature and immunostained for GluR1, ADAM10, and Pan-Shank as the postsynaptic marker; primary and secondary antibodies were applied in GDB buffer (30 mM phosphate buffer, pH 7.4, containing 0.2% gelatin, 0.5% Triton X-100, and 0.8 M NaCl) (Sala et al., 2001 ). Cells were chosen randomly for quantification from four different coverslips (two independent experiments), and 10 neurons for each treatment were analyzed. Fluorescence images were acquired by using the confocal LSM510 Meta system (Zeiss) with a 63ϫ objective and a sequential acquisition setting at 1024 ϫ 1024 pixel resolution; colocalization analysis was performed with the confocal software (Zeiss).
Morphological analysis of in vivo experiments was conducted by using a diolistic gene gun system to propel DiI-coated particles into sections of fixed brain tissue. Images of DiI-labeled structures in hippocampal CA1 stratum radiatum were acquired using the LSM510 confocal microscope (Zeiss). At least 10 z-stack images were acquired for each animal and for each area of interest. Morphometric analysis of dendritic spines was performed with MetaMorph software.
Live imaging. Time-lapse imaging occurred in an environmentally controlled chamber with 5% carbon dioxide at 37°C, and images were obtained using the confocal LSM510 Meta system (Zeiss) with a 63ϫ objective and zoom function set on 4; for each image, three to four 1 m sections were acquired, and z-projection was obtained. Images were acquired every 3 min for 30 min of nontreated cells used as the control, after injection of TAT-Pro or TAT-Ala peptide images were acquired every 3 min for 30 min. Head width of all spines was measured at each time point.
Electrophysiological recordings from CA1 pyramidal cells. Experiments were performed on parasaggital hippocampal slices from 14-to 16-d-old C57BL/6 mice by using standard techniques. Whole-cell voltage-clamp recordings (3.5-4.5 M⍀ electrodes) were made at 30 -32°C from pyramidal cells of the CA1 field visualized by infrared videomicroscopy. Slices were perfused with extracellular solution composed of 125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH 2 PO 4 , 26 mM NaHCO 3 , 2.3 mM CaCl 2 , 1.3 mM MgCl 2 , and 25 mM glucose saturated with 95% O 2 /5% CO 2 . Bicuculline (10 M) was added to the bath to block GABA A receptors. The intracellular solution was composed of 140 mM cesium methanesulfonate, 2 mM MgCl 2 , 4 mM NaCl, 5 mM phospho-creatine, 2 mM Na 2 ATP, 10 mM EGTA, 10 mM HEPES, and 0.33 mM GTP, pH 7.3. In experiments in which the rectification indices (RIs) were measured, 1 mM QX314 and 0.1 mM spermine were also added to the intracellular solution. Evoked postsynaptic responses were induced in CA1 pyramidal cells by stimulating Schaffer collaterals in stratum radiatum (0.1 Hz) with a monopolar glass pipette. In experiments shown in Figure 5 , nonpermeable ADAM10 Pro and Ala peptides were delivered postsynaptically through the recording pipette. We waited 15 min after establishing the whole-cell configuration before starting the recording to ensure adequate diffusion of reagents into dendritic compartments. RIs were calculated by plotting the magnitude of the average EPSC at Ϫ60, 0, and ϩ40 mV and taking the ratio of the slope of the lines connecting values at 0 -40 and at Ϫ60 to 0 mV. This calculation, with respect to the simple ratio of EPSC amplitude at ϩ40/Ϫ60 mV, takes into account the variable AMPA receptor reversal potential of each recording (Adesnik and Nicoll, 2007) . In experiments shown in Figure 8 , mice were given intraperitoneal injections of ADAM10 TAT-Ala or TAT-Pro peptides (3 nmol/g) 24 h before slice preparation. AMPA receptor EPSCs were recorded at Ϫ80 mV. NMDA receptor EPSCs were recorded at ϩ40 mV and measured 40 ms after the initiation of the EPSC, a time point at which AMPA receptor-mediated currents are absent or minimal. Small hyperpolarizing voltage steps were given before each afferent stimulus allowing on-line monitoring of input and series. Values are expressed as mean Ϯ SEM.
Quantification and statistical analysis. Quantification of Western blot analysis was performed by means of computer-assisted imaging (ImageJ) after normalization on actin or tubulin levels, and values were expressed as mean Ϯ SEM. Colocalization analysis was performed using AIM 4.2 software (Zeiss).
Statistical evaluations were performed by using the unpaired Student's t test or, when appropriate, by using one-way ANOVA (Fig. 2 D-F , 3, 4G, and 9E), followed by Bonferroni's post hoc test.
For electrophysiological experiments shown in Figure 5 , we used twoway ANOVA among groups perfused with Pro and Ala peptide and the unpaired Student's t test for the last 2 min of recording. For electrophysiological experiments shown in Figure 8 , the unpaired Student's t test was used for data comparison.
Results

ADAM10/SAP97 interaction is required for ADAM10-mediated cleavage of synaptic N-cadherin
First, we asked whether constitutive ADAM10-mediated cleavage of N-cadherin occurs at synapses of primary hippocampal neurons during neuronal development (DIV10). To this, we interfered with ADAM10 activity by means of a previously char- acterized cell-permeable peptide (Marcello et al., 2007) , in which the TAT cell-permeable domain is fused to the C-terminal proline-rich domains of ADAM10 (TAT-Pro) (supplemental Fig.  1 A, available at www.jneurosci.org as supplemental material). TAT-Pro peptide competes with endogenous ADAM10 for the binding to the SH3 domain of SAP97 and disrupts the endogenous ADAM10/SAP97 complex (Marcello et al., 2007) . The ADAM10/SAP97 complex is responsible for the enzyme localization and activity at synaptic membranes, and treatment with the peptide is able to reduce both ADAM10 localization and activity at synapses (Marcello et al., 2007) . As the control, an analogous inactive peptide in which all proline residues were substituted by alanines was used (TAT-Ala). Coimmunoprecipitation experiments were performed after treatment of primary hippocampal neurons (DIV10) with TAT-Pro or TAT-Ala peptides (10 M, 30 min) (Fig. 1 A) . A reduction in ADAM10/SAP97 coimmunoprecipitation was observed in neurons treated with TAT-Pro inhibitory peptide, indicating a decreased presence of the ADAM10/ SAP97 complex (Fig. 1 A) (TAT-Pro vs TAT-Ala, Ϫ29.2 Ϯ 1.1%; p Ͻ 0.005). Under these experimental conditions, we found no modifications of SAP97 and ADAM10 levels in total homogenate, suggesting that the observed uncoupling can be ascribed to a decreased association rather than to changes in levels of these proteins (Fig. 1 B) . A significant reduction in ADAM10 in TIF, enriched in proteins of the postsynaptic density (Gardoni et al., 2009 ) was observed ( Fig. 1C ; TAT-Pro vs TAT-Ala, Ϫ39.6 Ϯ 5.8%; p Ͻ 0.0005), indicating a decreased ADAM10 synaptic localization. Biochemical data were also confirmed by immunocytochemical labeling of ADAM10 in hippocampal neurons (DIV10). As shown in Figure 1 D, treatment with Tat-Pro led to a reduction in ADAM10 punctate staining in Shank-positive clusters (TAT-Pro vs TAT-Ala, Ϫ45.3 Ϯ 8.3%; p Ͻ 0.05).
To check TAT-Pro specificity to disrupt the ADAM10/SAP97 complex without influencing other protein-protein interactions, Figure 4 . Role of ADAM10 synaptic localization on AMPA receptor composition. A, Acute hippocampal slices were treated with TAT-Pro or TAT-Ala ADAM10 peptides (10 M, 30 min). Total homogenate was immunoprecipitated with an antibody against ADAM10, and Western blot analysis for SAP97 was performed: treatment with TAT-Pro inhibitory peptide reduced SAP97 coimmunoprecipitation with ADAM10 ( p Ͻ 0.005; n ϭ 3). B, Treatment with TAT-Pro induced a statistically significant decrease in ADAM10 localization in the TIF ( p Ͻ 0.05; n ϭ 5). C, TAT-Pro inhibitory peptide induced an increase in the FL/CTF N-cadherin ratio ( p Ͻ 0.05; n ϭ 3) compared with TAT-Ala. D, Western blot analysis performed in the TIF shows a statistically significant increase in GluR1 ( p Ͻ 0.0001; n ϭ 6), but no modification of the GluR2 ( p ϭ 0.9399; n ϭ 6) subunit of AMPA receptor. E, Western blot analysis shows no modification of NMDA receptor subunits in TIF after treatment with TAT-Pro (NR1, p ϭ 0.9728; NR2A, p ϭ 0.4375; NR2B, p ϭ 0.9839; n ϭ 4). F, Immunolabeling of primary hippocampal neurons for GluR1 (green) and Shank (red); TAT-Pro increased GluR1/Shank colocalization ( p Ͻ 0.0005, n ϭ 10). G, Immunolabeling of primary hippocampal neurons for GluR1 (red) and Shank (blue); transfection with N-cadherin GD but not with N-cadherin Wt increased GluR1/Shank colocalization ( p Ͻ 0.0002 among groups, p Ͻ 0.002 GD vs GFP, p Ͻ 0.0002 GD vs Wt; n Ͼ 21 from 3 independent experiments for each group).
we tested SAP97 SH3 domain capability to bind to other partners in the presence of TAT-Pro. No alterations were found in the association between Akap150 and SAP97 (supplemental Fig. 1 B, available at www.jneurosci.org as supplemental material). TATPro did not interfere with the binding of other synaptic SH3 to Pro-rich domains, as assessed by coimmunoprecipitation of PYK2 and PSD-95 (supplemental Fig. 1C , available at www.jneurosci.org as supplemental material). On the whole, these data confirm that TAT-Pro is specific for its capability to interfere with the ADAM10/ SAP97 complex (Marcello et al., 2007) .
We then investigated whether the observed decrease in ADAM10 synaptic localization after TAT-Pro treatment was associated with inhibition of ADAM10 activity toward N-cadherin. By using an antibody raised against the N-cadherin C-terminal intracellular domain (C-32), we detected two main immunoreactive bands corresponding to the full-length (FL) N-cadherin and to its CTF, which has previously been described as deriving from ADAM10-mediated cleavage (Reiss et al., 2005; Uemura et al., 2006) . After treatment with TAT-Pro, an increase in N-cadherin FL (Fig. 1 E) (TAT-Pro vs TAT-Ala, ϩ42.6 Ϯ 12.7%; p Ͻ 0.05), a concomitant decrease in N-cadherin CTF (Fig. 1 E) (TAT-Pro vs TAT-Ala, Ϫ32.5 Ϯ 8.6%; p Ͻ 0.05), and a consequent increase in the FL/CTF ratio (Fig. 1 E) (TAT-Pro vs TAT-Ala, ϩ90.1 Ϯ 10.7%; p Ͻ 0.005) were observed, compared to TAT-Ala.
Thus, interfering with ADAM10 localization and activity at the postsynaptic membrane by means of TAT-Pro, we demonstrated that constitutive ADAM10-mediated cleavage of N-cadherin indeed occurs at synapses of primary hippocampal neurons during development.
ADAM10 localization and activity at synapse influence spine morphology
Since N-cadherin signaling leads to modulation of spine morphology and synapse stability (Abe et al., 2004; Xie et al., 2008; Mendez et al., 2010) , we asked whether the increased synaptic accumulation of N-cadherin FL, as obtained by TAT-Pro treatment, could be paralleled by modifications of spine morphology.
DIV7 GFP-transfected hippocampal neurons were incubated, at DIV10, with TAT-Pro or TAT-Ala (10 M, 30 min). After treatment, cells were fixed and immunolabeled with an anti-GFP antibody (Fig. 2 A) , and average spine head width and number of dendritic spines were evaluated. Statistical analysis revealed a significant increase in spine head width (Fig. 2 B) ( p Ͻ 0.0005) after treatment with TAT-Pro, and cumulative frequency plots of spine head width confirmed a significant shift toward bigger spine size (Fig. 2C) . No changes in the mean spine density were found (TAT-Ala, 3.75 Ϯ 0.29 spines/10 m; TAT-Pro, 4.10 Ϯ 0.18 spines/10 m; p ϭ 0.1853).
To confirm that the effects of ADAM10 inhibition on spine size are dependent on N-cadherin cleavage, we repeated morphological analysis in neurons after transfection with GFP, with GFP-N-cadherin Wt, or with the cleavage-defective GFP-N-Cadherin GD construct, mutated in the ADAM10 cleavage site (Uemura et al., 2006) . Both N-cadherin constructs showed the same expression pattern at the postsynaptic site as demonstrated by colocalization analysis with Shank-positive clusters (data not shown).
Statistical analysis revealed a significant increase in spine head width in GFP-N-cadherin GD but not in GFP N-cadherin Wt transfected neurons (Fig. 2 D-F ) ( p Ͻ 0.0001 among groups, p Ͻ 0.001 GD vs GFP, p Ͻ 0.0001 GD vs Wt), thus confirming that blocking ADAM10-dependent cleavage of N-cadherin leads per se to an increase in spine size.
After confirming that the increase in spine width is attributable to the blocking of ADAM10 cleavage of N-cadherin, we investigated the onset of the effect by time-lapse imaging. In basal conditions, no significant modification of average spine head width was observed over 30 min (Fig. 3 A, B) . Similarly, treatment with TAT-Ala did not induce any modification of spine size. An increase in spine head width (Fig. 3A,B) , which became statistically significant 18 min after treatment, was observed in TAT-Pro-treated neurons if compared with control and TAT-Ala-treated ones ( Is this morphological effect of TAT-Pro treatment dependent on spine size? Evaluation of spine head width in DIV10 primary hippocampal neurons revealed that 0.8 m represents a cutoff value that allowed to split spines into two equal populations (supplemental Fig. 2 , available at www.jneurosci.org as supplemental material). As shown in Figure 3C , even if the absolute differences were bigger for spines smaller than the cutoff value, both groups showed a significant increase in spine head width 30 min after treatment with TAT-Pro compared with control and TAT-Alatreated neurons (width Ͻ0.8 m: p Ͻ 0.01 among groups, p Ͻ 0.01 TAT-Pro vs control, p Ͻ 0.05 TAT-Pro vs TAT-Ala; width Ն0.8 m: p Ͻ 0.0001 among groups, p Ͻ 0.0001 TAT-Pro vs control, p Ͻ 0.005 TAT-Pro vs TAT-Ala). Furthermore, a significant increase in the percentage of growing spines ( p Ͻ 0.01 among groups, p Ͻ 0.05 TAT-Pro vs control, p Ͻ 0.01 TAT-Pro vs TATAla) and a corresponding decrease in the percentage of shrinking ones ( p Ͻ 0.01 among groups, p Ͻ 0.05 TAT-Pro vs control, p Ͻ 0.01 TAT-Pro vs TAT-Ala) was detectable 30 min after treatment with TAT-Pro compared with control and TAT-Ala (Fig. 3D) . ADAM10 localization and activity influence subunit composition of synaptic AMPA receptors N-Cadherin regulates the number of AMPA receptors at synapses (Liao et al., 1999; Togashi et al., 2002; Kasai et al., 2003) and can interact with specific subunits of AMPA receptors (Dunah et al., 2005; Nuriya and Huganir, 2006; Saglietti et al., 2007) . More recently, it has been shown that N-cadherin inactivation results in fewer GluR1 synaptic clusters (Xie et al., 2008) .
To test whether this N-cadherin-dependent modulation of AMPA receptor composition at synapses is associated with ADAM10-mediated N-cadherin cleavage, hippocampal slices from 3-week-old rats were incubated with TAT-Pro or TAT-Ala for 30 min. As for primary neurons (Fig. 1) , we first validated our Figure 6 . Inhibition of ADAM10 activity by TIMP-1 decreases ADAM10-mediated N-cadherin processing and induces a modification of AMPA receptors at synapses. A, TIMP-1 (15 nM, 30 min) induced a statistically significant increase in N-cadherin FL in the TIF ( p Ͻ 0.05; n ϭ 4), a concomitant decrease in CTF ( p Ͻ 0.01; n ϭ 4), and a consequent increase in the FL/CTF ratio ( p Ͻ 0.005; n ϭ 4). B, DIV10 primary hippocampal neurons were immunolabeled for ADAM10 (green) and Shank (red). No modification of GluR1/Shank colocalization was observed after treatment with TIMP-1 ( p ϭ 0.3637; n ϭ 10). C, Western blot analysis performed on TIF with antibodies against ADAM10 and SAP97: no change in ADAM10 ( p ϭ 0.2240, n ϭ 6) and SAP97 ( p ϭ 0.9118, n ϭ 5) levels was observed. D, Primary hippocampal neurons were transfected with enhanced GFP construct (DIV7) and treated or not at DIV10 with TIMP-1 (15 nM, 30 min). Representative images show dendrites from control and TIMP-1-treated neurons. Scale bar, 10 m. E, Diagram showing relative average spine head width (*p Ͻ 0.0001, TIMP-1 vs control; n Ͼ 500 spines from 9 different neurons for each condition). F, Cumulative frequency plots from control and TIMP-1-treated neurons. G, Western blot analysis performed in the TIF showed a statistically significant increase in GluR1 ( p Ͻ 0.0001; n ϭ 5) but no modification of the GluR2 ( p ϭ 0.8481; n ϭ 5) subunit of AMPA receptor. H, Primary hippocampal neurons immunolabeling for GluR1 (green) and Shank (red). Neurons treated with TIMP-1 showed a statistically significant increase in GluR1/Shank colocalization ( p Ͻ 0.005; n ϭ 10).
tool: in hippocampal slices, treatment with TAT-Pro decreased ADAM10 interaction with SAP97 (Fig. 4 A) (TAT-Pro vs TATAla, Ϫ59.5 Ϯ 9.9%; p Ͻ 0.005), decreased ADAM10 localization in the TIF (Fig. 4 B) (TAT-Pro vs TAT-Ala, Ϫ35.3 Ϯ 10.4%; p Ͻ 0.05) and, as a direct consequence, increased the N-cadherin FL/ CTF ratio (Fig. 4C ) (TAT-Pro vs TAT-Ala, ϩ53.9 Ϯ 16.4%; p Ͻ 0.05).
In hippocampal slices treated with TAT-Pro, the GluR2 subunit of AMPA receptor (Fig. 4 D) , as well as all tested NMDA receptor subunits (Fig. 4 E) , did not show any modification of their localization in the postsynaptic compartment. Instead, GluR1 levels showed a specific and significant increase in TIF (Fig. 4 D) (TAT-Pro vs TAT-Ala, ϩ30.7 Ϯ 3.2%; p Ͻ 0.0001). This result was confirmed in hippocampal neurons treated with TAT-Pro where increased GluR1 localization in Shank-positive clusters was detectable (Fig. 4 F) (TAT-Pro vs TAT-Ala, ϩ39.0 Ϯ 6.7%; p Ͻ 0.005). To demonstrate that the observed effect is dependent on N-cadherin cleavage, we repeated GluR1/Shank colocalization assay in neurons transfected with GFP, with GFP-N-cadherin Wt, or with the cleavage-defective GFP-N-cadherin GD construct. Statistical analysis revealed a significant increase in GluR1 levels in Shank-positive clusters in GFP-N-cadherin GD but not in GFP N-cadherin Wt transfected neurons (Fig. 4G) ( p Ͻ 0.0002 among groups, p Ͻ 0.002 GD vs GFP, p Ͻ 0.0002 GD vs Wt) compared with control.
ADAM10 localization and activity influence synaptic AMPA receptor function
Since interfering with ADAM10 activity at synapses leads to modification of the composition of AMPA receptors, we tested whether it is also capable of modifying AMPA receptor function. To this, we delivered postsynaptically nonpermeable Pro and Ala peptides (same effector sequence as TAT-Pro and TAT-Ala, respectively, but not bound to TAT-cargo domain) through the patch pipette while monitoring AMPA receptor-mediated EPSCs evoked by stimulation of Schaffer collaterals in CA1 pyramidal cells in the presence of bicuculline (10 M) and D-AP-5 (50 M). Thirty minutes after intracellular perfusion with Pro peptide, cells showed a significant increase in EPSC amplitudes compared with cells dialyzed with Ala peptide (Fig. 5 A, B) ( p Ͻ 0.0001). In a subset of experiments, we evaluated the contribution of AMPA receptors lacking the GluR2 subunit to the EPSCs measuring the RI at the beginning (0 min) and at the end (30 min) of the experiment (Fig. 5 A, C) (at Ϫ60, 0, and ϩ40 mV). RI values observed for both peptides at 0 min (Fig. 5 A, C) (Pro, 0.84 Ϯ 0.06; Ala, 0.92 Ϯ 0.05) were similar to those previously observed at this age in CA1 pyramidal cells (Adesnik and Nicoll, 2007) . No significant change in RI was observed in cells dialyzed for 30 min with Pro or Ala ADAM10 peptides (Fig. 5 A, C) (Pro peptide, p ϭ 0.4; Ala peptide, p ϭ 0.37). Therefore, inhibition of ADAM10/SAP97 interaction not only induces a rise in GluR1 localization in the TIF but also increases the amplitude of AMPA receptor-mediated EPSCs, which do not appear to be mediated by an insertion of GluR2-lacking AMPA receptors.
Inhibition of ADAM10 activity by treatment with TIMP-1 results in decreased ADAM10-mediated N-cadherin processing and in a modification of AMPA receptors at synapses
To confirm the results obtained by using TAT-Pro peptide, we performed a pharmacological inhibition of ADAM10 activity by using TIMP-1 (Amour et al., 2000) in DIV10 hippocampal neurons.
As TAT-Pro peptide did, TIMP-1 treatment (15 nM, 30 min) also caused an increase in N-cadherin FL (Fig. 6 A) (TIMP-1 vs Figure 7 . In vivo modulation of ADAM10/SAP97 interaction. A, TAT-Ala and TAT-Pro ADAM10 peptides were injected in vivo (3 nmol/g, 24 h; 14-d-old mice). Total homogenate was immunoprecipitated (IP) with an antibody against ADAM10, and Western blot (WB) analysis was performed with an antibody against SAP97. B, ADAM10 (TAT-Pro vs TAT-Ala, p Ͻ 0.05; 22 animals from 3 independent experiments), but not SAP97 ( p ϭ 0.0533; 22 animals from 3 independent experiments), was decreased in the TIF purified from animals treated with TAT-Pro inhibitory peptide compared with animals treated with TAT-Ala. C, Western blot analysis performed in the TIF with antibodies against N-cadherin after 24 h in vivo treatment with TAT-Pro and TAT-Ala peptides. N-cadherin FL/CTF ratio in TIF was statistically increased ( p Ͻ 0.05; 22 animals from 3 independent experiments) in animals treated with TAT-Pro compared with animals treated with TAT-Ala. D, Morphological analysis of dendritic spines was conducted using a diolistic gene-gun system to propel DiI-coated particles into hippocampal sections of fixed brain tissue of TAT-Pro-and TAT-Alatreated mice. Scale bar, 10 m. E, Diagram of average spine head width (*p Ͻ 0.005, TAT-Pro vs TAT-Ala; n Ͼ 900 spines from 18 neurons from 4 different animals for each condition). F, Cumulative frequency plots from neurons treated with TAT-Ala and TAT-Pro ADAM10 peptides.
control, ϩ37.6 Ϯ 14.5%; p Ͻ 0.05), a concomitant decrease in N-cadherin CTF (Fig. 6 A) (TIMP-1 vs control, Ϫ38.6 Ϯ 9.5%; p Ͻ 0.01), and a consequent increase in the FL/CTF ratio (Fig.  6 A) (TIMP-1 vs control, ϩ131.5 Ϯ 23.7%; p Ͻ 0.005). As expected, TIMP-1 did not induce any modification of ADAM10 localization at synaptic sites, as demonstrated by both immunocytochemical analysis (Fig. 6 B) ( p ϭ 0.3637) and Western blot analysis on TIF (Fig. 6C) ( p ϭ 0.2240) . Furthermore, treatment with TIMP-1 significantly increased spine head width (Fig.  6 D, E) ( p Ͻ 0.0001), as confirmed by cumulative frequency plots analysis (Fig. 6 F) . As for TAT-Pro treatment, no changes in the mean spine density were found. Again, in TIMP-1-treated neurons, GluR1 levels were significantly increased in the postsynaptic membranes (Fig. 6G ) (TIMP-1 vs control, ϩ32.2 Ϯ 5.3%; p Ͻ 0.0001), and GluR1 localization was higher in Shank-positive clusters compared with controls ( Fig. 6H ) (TIMP-1 vs control, ϩ48.9 Ϯ 7.6%; p Ͻ 0.005).
In vivo modulation of ADAM10/SAP97 interaction The above-described results indicate that inhibition of ADAM10 activity in the postsynaptic compartment in primary hippocampal neurons and in acute hippocampal slices leads to an increase in the synaptic levels of N-cadherin FL and in spine head width and to a modification of AMPA receptor currents and composition at synapse.
To assess the role of ADAM10 activity in modulating longlasting rearrangements of glutamatergic synapse during development, we performed an in vivo treatment with TAT-Pro in young mice (2 weeks old). As shown in Figure 7A , 24 h after intraperitoneal administration of TAT-Pro (3 nmol/g) (Marcello et al., 2007) , ADAM10 interaction with SAP97 was reduced (Marcello et al., 2007) as well as the ADAM10 amount at synaptic sites (Fig.  7B ) (TAT-Pro vs TAT-Ala, Ϫ34.7 Ϯ 4.4%; p Ͻ 0.05) with no modification of SAP97 levels (Fig. 7B) . In addition, 24 h after administration of TAT-Pro, the N-cadherin FL/CTF ratio was increased at synapse (Fig. 7C ) (TAT-Pro vs TAT-Ala, ϩ110.3 Ϯ 16.7%; p Ͻ 0.05), indicating a reduction in ADAM10-mediated N-cadherin cleavage.
Morphological analysis of the size of dendritic spines was conducted using a diolistic gene gun system to propel DiI-coated particles into hippocampal sections of fixed brain tissue of TATPro-and TAT-Ala-treated mice (Fig. 7D-F ) . Statistical analysis revealed a significant increase in spine head width (Fig. 7E) ( p Ͻ 0.005) after treatment with TAT-Pro and cumulative frequency plots of spine head width confirmed the significant shift toward bigger spines (Fig. 7F ) . A significant decrease in the mean spine density was also found after in vivo TAT-Pro treatment (TATAla, 6.72 Ϯ 0.46 spines/10 m; TAT-Pro, 5.53 Ϯ 0.31 spines/10 m; p Ͻ 0.05).
Moreover, mice treated with TAT-Pro peptide showed a significant increase in the levels of the GluR1 subunit of AMPA receptor (Fig. 8 A) (TAT-Pro vs TAT-Ala, ϩ38.1 Ϯ 7.6%; p Ͻ 0.05) in the postsynaptic compartment when compared to TATAla-treated ones. No changes in synaptic abundance of GluR2 AMPA receptor subunit (Fig. 8 A) and of NMDA receptor subunits (Fig. 8 B) were found 24 h after in vivo treatment with TATPro. No modification of any tested protein was observed in the total homogenate (supplemental Fig. 3A -C, available at www. jneurosci.org as supplemental material).
To confirm that the above-described modification of GluR1 localization at synapse is mediated by the ADAM10/N-cadherin pathway and not by an a specific effect of TAT-Pro on SAP97 interaction with GluR1 (Gardoni et al., 2003; Waites et al., 2009 ), a coimmunoprecipitation assay was performed: mice treated with TAT-Pro showed no modification of the GluR1/SAP97 complex compared with animals treated with TAT-Ala (supplemental Fig. 4 , available at www.jneurosci.org as supplemental material).
Again, as we did in vitro, we tested whether impairing ADAM10-mediated cleavage of N-cadherins in vivo was accompanied by changes in synaptic currents. Fourteen-day-old mice were given intraperitoneal injections of either TAT-Pro or TATAla peptides (3 nmol/g), and hippocampal slices were prepared 24 h later. AMPA and NMDA receptor-mediated EPSCs were recorded from CA1 pyramidal cells, respectively, at Ϫ80 and ϩ40 mV. The NMDA receptor-mediated contribution was measured 40 ms after initiation of the EPSC, a time point at which AMPA receptor-mediated EPSCs are absent or minimal. Treatment of mice with TAT-Pro induced a significant increase in the AMPA/ NMDA ratio compared with TAT-Ala treatment (Fig. 8C,D) ( p Ͻ 0.05). No significant differences were observed in the decay times of EPSCs recorded at Ϫ80 and ϩ40 mV. 
Synaptic activity modulates ADAM10-mediated N-cadherin cleavage
We demonstrated in vitro and in vivo that, under basalunstimulated conditions, inhibition of ADAM10-dependent N-cadherin cleavage leads to a specific and long-lasting modification of the morphology of the glutamatergic synapse as well as of AMPA receptor subunit composition and function.
We then asked whether these mechanisms could be modulated by synaptic activity. To this, DIV10 hippocampal neurons were treated with bicuculline (50 M, 30 min). After treatment, TIF was purified and analyzed by Western blot. As shown in Figure 9A , neurons stimulated with bicuculline showed a significant increase in ADAM10 levels in the TIF (bicuculline vs control, ϩ71.0 Ϯ 20.5%; p Ͻ 0.005).
Since ADAM10 is active only when inserted into the postsynaptic membrane, we performed a surface assay with the crosslinker BS 3 after treatment with bicuculline: in lysates of neurons treated with bicuculline, the intracellular amount of ADAM10 was decreased compared with control cells (Fig. 9B ) (bicuculline vs control, Ϫ36.3 Ϯ 6.2%; p Ͻ 0.05), indicating an increased insertion of the enzyme into the membrane. As expected, the increased ADAM10 localization in the postsynaptic membrane was associated with a decrease in the N-cadherin FL/CTF ratio ( Fig. 9C ) (bicuculline vs control, Ϫ41.4 Ϯ 6.7%; p Ͻ 0.00005).
On the other hand, treatment with TTX (2 M, 30 min), a neural activity blocker, led to decreased ADAM10 levels at synapses (Fig.  9D ) (TTX vs control, Ϫ31.3 Ϯ 7.4%; p Ͻ 0.01) that were not paralleled by any modification of the N-cadherin FL/CTF ratio and GluR1 levels at synapses (Fig. 9D ). Moreover, 3 h TTX treatment did not result in any modification of ADAM10 levels at synaptic sites as well as of N-cadherin and GluR1 (see also Sutton et al., 2006; Turrigiano et al., 1998) , suggesting that TTX induces only a transient effect on ADAM10 localization at synaptic sites not sufficient to affect the N-cadherin/GluR1 pathway (data not shown). , a membrane-impermeable amine-reactive cross-linker reagent, on primary hippocampal neurons after stimulation with bicuculline (50 M, 30 min). Western blot analysis shows a significant decrease in the intracellular amount of ADAM10 ( p Ͻ 0.05; n ϭ 3) in neurons treated with bicuculline compared with control cells; all data have been normalized using tubulin. ADAM10 surface pool was not detectable because of the formation of high-molecularweight aggregates that did not enter the gel. C, Stimulation with bicuculline (50 M, 30 min) induced a statistically significant decrease in the N-cadherin FL/CTF ratio ( p Ͻ 0.00005; n ϭ 13). D, Western blot analysis performed in TIF after treatment with TTX (2 M, 30 min); TTX treatment induced a statistically significant decrease in ADAM10 amount ( p Ͻ 0.01; n ϭ 7) but no modification of GluR1, GluR2 and the N-cadherin FL/CTF ratio. E, Primary hippocampal neurons were incubated or not with the ADAM10-specific inhibitor peptide TIMP-1 (15 nM, 1 h) and stimulated with bicuculline (50 M, 30 min); untreated cells were used as the control. Neurons pretreated or not with TIMP-1 and stimulated with bicuculline showed a statistically significant increased amount of ADAM10 in the TIF compared with controls ( p Ͻ 0.01 among groups; *p Ͻ 0.005, bicuculline vs control; # p Ͻ 0.05, TIMP-1 plus bicuculline vs control; n ϭ 7). Neurons stimulated with bicuculline showed statistically significant modification of the N-cadherin FL/CTF ratio ( p Ͻ 0.05 among groups; *p Ͻ 0.0005, bicuculline vs control; # p Ͻ 0.05, TIMP-1 plus bicuculline vs bicuculline; n ϭ 7; one-way ANOVA, followed by Bonferroni's as a post hoc comparison test) compared with control and TIMP-1-treated cells. F, Western blot analysis performed in TIF with antibodies against ADAM10 and the C-terminal region of N-cadherin. Primary hippocampal neurons (DIV10) were incubated with both TAT-Ala and TAT-Pro ADAM10 peptides for 2 min and stimulated with bicuculline (50 M, 30 min). Neurons pretreated with TAT-Pro inhibitory peptide showed a statistically significant decrease in ADAM10 localization in the TIF ( p Ͻ 0.005, TAT-Pro vs TAT-Ala; n ϭ 5) and a consequent increase in the N-cadherin FL/CTF ratio ( p Ͻ 0.05, TAT-Pro vs TAT-Ala; n ϭ 5) compared with TAT-Ala pretreated cells. Bic, Bicuculline.
ADAM10 activity is needed for activity-dependent N-cadherin processing
To verify whether the above-described bicuculline-induced N-cadherin cleavage in neurons was mediated by ADAM10, bicuculline treatment was repeated in the presence or absence of TIMP-1. DIV10 hippocampal neurons were treated with TIMP-1 (15 nM, 1 h) and stimulated with bicuculline (50 M, 30 min). As expected, stimulation with bicuculline increased ADAM10 localization to the postsynaptic compartment in the absence and in the presence of TIMP-1 (Fig. 9E) ( p Ͻ 0.01 among groups; bicuculline vs control, ϩ108.6 Ϯ 24.2%, p Ͻ 0.005; TIMP-1, ϩ bicuculline vs control, ϩ72.0 Ϯ 19.2%, p Ͻ 0.05), but pretreatment with TIMP-1 prevented the increase of ADAM10-mediated N-cadherin cleavage induced by bicuculline (Fig. 9E ) (FL/CTF: p Ͻ 0.05 among groups; bicuculline vs control, Ϫ40.4 Ϯ 11.3%, p Ͻ 0.0005; TIMP-1, ϩ bicuculline vs bicuculline, ϩ134.6 Ϯ 40.6%, p Ͻ 0.05). Thus, TIMP-1 blocks activity-dependent cleavage of N-cadherin mediated by ADAM10 without affecting ADAM10 subcellular localization.
Since bicuculline increases ADAM10 localization to the postsynaptic membrane and its activity on N-cadherin and since ADAM10 localization in TIF is regulated by SAP97, we asked whether SAP97 was involved in the bicuculline-dependent regulation of ADAM10 cleavage on N-cadherin. To this, primary hippocampal neurons (DIV10) were pretreated with TAT-Pro or TAT-Ala (2 min) and stimulated with bicuculline (50 M, 30 min). As shown in Figure 9F , TAT-Pro treatment reduced ADAM10 (TAT-Pro vs TAT-Ala, Ϫ45.6 Ϯ 7.5%; p Ͻ 0.005) localization in TIF also in neurons pretreated with bicuculline. Accordingly, the reduced ADAM10 localization in the postsynaptic membrane was associated with an enhanced N-cadherin FL/CTF ratio (Fig. 9F ) (TAT-Pro vs TAT-Ala, ϩ103.2 Ϯ 33.5%; p Ͻ 0.05). These results indicate the binding to SAP97 as necessary also for activitydependent localization of ADAM10 at synaptic sites.
Discussion
Here we demonstrate that synaptic activity of an enzyme belonging to the disintegrin and metalloproteinase family, ADAM10, represents a new way to regulate the number and function of AMPA receptors at hippocampal excitatory synapses (Fig. 10) . Interfering with ADAM10 localization at synapses is sufficient to induce a significant decrease in ADAM10-mediated N-cadherin cleavage, leading to accumulation of N-cadherin FL. This molecular event correlates with an increase in spine head width and with a modification of AMPA receptor currents and subunit composition both in vitro and in vivo.
The existence of a close coordination among N-cadherin, spine size, and AMPA receptor content has been put forward: Ncadherin activation results in more AMPA receptors and, consequently, in bigger and stable synapses (Kasai et al., 2003; Kopec et al., 2007; Xie et al., 2008) . Here we show that ADAM10-dependent cleavage of N-cadherin represents an upstream event of these pathways. Inhibition of ADAM10-mediated processing of N-cadherin induces a significant increase in spine head width in both small-immature and large-mature spines, as observed within 30 min in time-lapse experiments. Interestingly, spine enlargement starts 18 min after stabilization of N-cadherin FL and remains stable up to 30 min after ADAM10 inhibition.
Notably, these observations have been confirmed by in vivo experiments. The TAT-Pro peptide used in the present study is a useful tool not only for in vitro but also for in vivo studies. This is of relevance because in vivo study of N-cadherin processing was formerly hampered by the lack of sensitive tools. In particular, here we show that the in vivo effect of ADAM10 inhibition on spine morphology is quite long-lasting and stable, being significant still 24 h after treatment.
It has been shown that accumulation of N-cadherin FL results in more GluR1 synaptic clusters, whereas N-cadherin inactivation results in less GluR1 clusters (Xie et al., 2008) . Accordingly, our results show that 30 min after stabilization of the full-length form of N-cadherin, a significant recruitment of GluR1 into the postsynaptic compartment is detectable. No significant changes in the RI were observed in cells dialyzed with ADAM10 inhibitory peptide, suggesting the absence of any significant modification in the percentage of GluR2 containing AMPA receptors. This is only an apparent discrepancy between molecular and electrophysiological analysis; in fact, molecular analysis performed in the TIF allows detecting modifications of AMPA receptor subunits' levels at synaptic sites but does not give information on modifications of AMPA receptor subunit insertion/endocytosis taking place within the synaptic compartment. Moreover, the observed selective GluR1 augmentation (about 30%) could simply not lead to a detectable change in RI that can be observed only in the presence of homomeric GluR1 receptor.
Long-term persistence of the effect of ADAM10 inhibition on synaptic GluR1-containing AMPA receptors and on AMPA receptor currents was demonstrated by 24 h in vivo experiments, again confirming the close correlation between spine size and GluR1 levels.
The major issue of the present study is to analyze molecular, functional, and morphological outcomes of the ADAM10/Ncadherin pathway. Recent studies provided indications that ADAM10 is responsible for the first step of the proteolytic processing of N-cadherin, leading to the generation of the CTF1 fragment (Reiss et al., 2005; Uemura et al., 2006) . In the present study, we show that transfection of hippocampal neurons with the cleavage-defective N-cadherin construct, mutated in the 
